{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:35:29Z","timestamp":1764714929954,"version":"3.37.3"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Fatigue is common and burdensome in antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV). This study aimed to understand how fatigue changes over time following treatment initiation and to determine whether individuals with the poorest prognosis can be robustly identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>One hundred forty-nine patients with AAV and new-onset disease recruited to 2 clinical trials (RITUXVAS and MYCYC) were followed for 18 months. Fatigue was measured at baseline and 6-month intervals using the vitality domain of the Medical Outcomes Study Short Form-36 quality of life questionnaire and compared to a cohort of 470 controls. Group-based trajectory modeling (GBTM) determined trajectories of the symptom to which baseline characteristics and ongoing fatigue scores were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Fatigue levels at diagnosis were worse in patients than controls [median (interquartile range; IQR) 30 (10\u201348) vs 70 (55\u201380); p &lt; 0.001], with 46% of patients reporting severe fatigue. Fatigue improved after 6 months of treatment but remained worse than in controls (p &lt; 0.001). GBTM revealed varied trajectories of fatigue: low fatigue stable (n = 23), moderate baseline fatigue improvers (n = 29), high baseline fatigue improvers (n = 61), and stable baseline high fatigue (n = 37). Participants who followed stable high fatigue trajectories had lower vasculitis activity compared to improvers, but no other demographic or clinical variables differed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>This study longitudinally measured fatigue levels in patients with AAV. Although most patients improved following treatment, an important subgroup of patients reported persistently high levels of fatigue that did not change. Few clinical or laboratory markers distinguished these patients, suggesting alternative interventions specific for fatigue are required. [clinicaltrialsregister.eu, RITUXVAS EudraCT number: 2005-003610-15; MYCYC EudraCT number: 2006-001663-33]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.190113","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T16:15:12Z","timestamp":1561997712000},"page":"572-579","source":"Crossref","is-referenced-by-count":15,"title":["The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody\u2013associated Vasculitis"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4710-3475","authenticated-orcid":false,"given":"Lucy","family":"O\u2019Malley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie L.","family":"Druce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Chanouzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"2021110311500910000_47.4.572.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137778"},{"key":"2021110311500910000_47.4.572.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927"},{"key":"2021110311500910000_47.4.572.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.11471"},{"key":"2021110311500910000_47.4.572.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq098"},{"key":"2021110311500910000_47.4.572.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20276"},{"key":"2021110311500910000_47.4.572.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202750"},{"key":"2021110311500910000_47.4.572.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket483"},{"issue":"Suppl 70","key":"2021110311500910000_47.4.572.8","first-page":"S15","article-title":"The impact of vasculitis on patients\u2019 social participation and friendships","volume":"1","author":"Carpenter","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2021110311500910000_47.4.572.9","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/acr.22827","article-title":"Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"68","author":"McClean","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2021110311500910000_47.4.572.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket191"},{"key":"2021110311500910000_47.4.572.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew241"},{"key":"2021110311500910000_47.4.572.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141498"},{"key":"2021110311500910000_47.4.572.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"2021110311500910000_47.4.572.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214245"},{"key":"2021110311500910000_47.4.572.15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jclinepi.2012.09.009","article-title":"Alternative population sampling frames produced important differences in estimates of association: a case-control study of vasculitis","volume":"66","author":"Macfarlane","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2021110311500910000_47.4.572.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20471"},{"key":"2021110311500910000_47.4.572.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141143"},{"key":"2021110311500910000_47.4.572.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1148-2"},{"key":"2021110311500910000_47.4.572.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2003.12.006"},{"key":"2021110311500910000_47.4.572.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"2021110311500910000_47.4.572.21","first-page":"838","article-title":"Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis","volume":"25","author":"Yount","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2021110311500910000_47.4.572.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu390"},{"key":"2021110311500910000_47.4.572.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.37733"},{"key":"2021110311500910000_47.4.572.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq282"},{"key":"2021110311500910000_47.4.572.25","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/art.39238","article-title":"Determining pathways to improvements in fatigue in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"67","author":"Druce","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021110311500910000_47.4.572.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20243"},{"key":"2021110311500910000_47.4.572.27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1851::AID-ART18>3.0.CO;2-I"},{"key":"2021110311500910000_47.4.572.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20579"},{"key":"2021110311500910000_47.4.572.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes206"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:52:57Z","timestamp":1635965577000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.3899\/jrheum.190113"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190113","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}